Pressure mounts at GSK, with U.S. hedge fund leading calls for exec shakeup

Tracy Staton Another big investor is putting the screws to GlaxoSmith Kline. Och-Ziff Capital Management has built up a sizable stake in the London-based drugmaker, The Sunday Times ...

Valeant’s ill CEO Pearson on the ‘road to recovery,’ but still no timeline for his return

Carly Helfand Valeant's pneumonia-stricken CEO, J. Michael Pearson, is on the mend, according to a letter he penned to his colleagues on Monday. But as to when he'll be back ...

BMS’ Opdivo evens the score in melanoma with two new FDA green lights

Tracy Staton Thanks to an FDA decision over the weekend, Bristol-Myers Squibb's immunotherapy Opdivo has caught back up to Merck's Keytruda in melanoma. And it won a new combination ...

UPDATED: Hedge fund’s attack on troubled Zafgen draws blood

John Carroll These days, while success and victory still have 1,000 fathers, failure and defeat have its outspoken champions as well. FierceBiotech News

J&J loses bid to dismiss false advertising lawsuit over baby products

Carly Helfand Johnson & Johnson was hoping to put a marketing case around its Bedtime Products for babies to rest, but a federal judge isn't having it. FiercePharma News

GSK, AstraZeneca and J&J back $57M effort to springboard university drug research

John Carroll Three of the U.K.'s leading universities are joining hands with three of the world's biggest pharma giants to create a new translational medicine group aimed at ...

UPDATED: OncoMed hits the brakes on PhII pancreatic cancer trial, shares plummet

John Carroll OncoMed slammed the brakes on a Phase II study of the cancer stem cell drug tarextumab, citing worsening response rates in the drug arm for pancreatic cancer, with red ...

Shire gets back on track with once-rejected eye drug

Damian Garde Shire has resubmitted the once-rejected eye treatment lifitegrast for FDA approval, handing in new data the company hopes will get its self-described blockbuster drug onto ...

Editas tests CRISPR/Cas9 enthusiasm–and a turbulent market–with $122M IPO

John Carroll Despite facing one of the worst markets for biotech stocks in recent memory, Editas Medicine has taken another big step forward in its quest to raise some big bucks through ...

Soon-Shiong’s NantCell raises another $57M for immuno-oncology work

Damian Garde Billionaire entrepreneur Patrick Soon-Shiong's NantCell raised $ 57.3 million in equity to fund its work on treatments that use the immune system to fight cancer, ...

Merck teams with Affimed on immuno-oncology combo

John Carroll Germany’s Affimed has inked a deal that makes it the latest in a long string of biotechs to partner up with Merck on a combination study using the PD-1 blockbuster ...

Lawmaker to Martin Shkreli: Come to DC and take the 5th, in a live performance

John Carroll FierceBiotech News
Page 4 of 17« First...23456...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS